APA (7th ed.) Citation

YT, L., XC, T., FM, T., YY, K., MH, T., JH, L., . . . HF, T. (2026). Real-world experience with gilteritinib maintenance following allogeneic transplantation in relapsed/refractory AML patients harboring FLT3 mutations. Blood research, 61(1), . https://doi.org/10.1007/s44313-026-00144-3

Chicago Style (17th ed.) Citation

YT, Lin, et al. "Real-world Experience with Gilteritinib Maintenance Following Allogeneic Transplantation in Relapsed/refractory AML Patients Harboring FLT3 Mutations." Blood Research 61, no. 1 (2026). https://doi.org/10.1007/s44313-026-00144-3.

MLA (9th ed.) Citation

YT, Lin, et al. "Real-world Experience with Gilteritinib Maintenance Following Allogeneic Transplantation in Relapsed/refractory AML Patients Harboring FLT3 Mutations." Blood Research, vol. 61, no. 1, 2026, https://doi.org/10.1007/s44313-026-00144-3.